Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 19/20 | 0.55 |
| ▸ | F2R | P25116 | 10/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936430 | 1.00 | ITGB3 (0.55) | ITGB3ITGA2BF2R | |
| SCHEMBL7496481 | 0.91 | ITGB3 (0.48) | ITGB3ITGA2BF2R | |
| SCHEMBL6539773 | 0.91 | ITGB3 (0.53) | ITGB3ITGA2BF2R | |
| SCHEMBL7444844 | 0.88 | ITGB3 (0.55) | ITGB3ITGA2BF2R | |
| SCHEMBL7818397 | 0.88 | ITGB3 (0.59) | ITGB3ITGA2BF2R | |
| SCHEMBL7436153 | 0.88 | ITGB3 (0.45) | ITGB3ITGA2BF2R | |
| SCHEMBL7501267 | 0.87 | ITGB3 (0.63) | ITGB3ITGA2BF2R | |
| SCHEMBL7508228 | 0.87 | ITGB3 (0.57) | ITGB3ITGA2BF2R | |
| SCHEMBL6538613 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BF2R | |
| SCHEMBL6538573 | 0.86 | ITGB3 (0.54) | ITGB3ITGA2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| US-6538007-B1 | Hydrates and method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed. antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0669912-B1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | ITGB3 52/4885ITGA2B 14/4885F2R 234/4885 |
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | BCAT1, BCAT2, AGXT | ITGB3 3266/4885ITGA2B 3019/4885F2R 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.